Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases

Autor:	Rahul S Dalal, Jordan C Pruce, Jessica R Allegretti
Rok vydání:	2022
Předmět:	Gastroenterology Immunology and Allergy
Zdroj:	Inflammatory Bowel Diseases. 29:830-833
ISSN:	1536-4844 1078-0998
DOI:	10.1093/ibd/izac164
Popis:	Lay Summary In this retrospective cohort study, we demonstrated that dose intensification of ustekinumab to every 4 or every 6 weeks was effective in both achieving and maintaining clinical remission for >40% of inflammatory bowel disease patients for up to 24 months.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60d2c3f38d8a8a4557fcf9cbc1e3265a https://doi.org/10.1093/ibd/izac164 Zobrazit plný text záznamu